Early test of engineered immune cells halted in pancreatic cancer fight
NCT ID NCT03323944
Summary
This early-phase study tested the safety of a new treatment called CAR T-cell therapy in adults with advanced pancreatic cancer that could not be removed by surgery. Doctors collected and modified patients' own immune cells to target cancer, then gave them back through an IV or directly into the abdomen or liver. The main goal was to see if this approach was safe and feasible, but the trial was later stopped.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.